Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Gene and immune therapy for renal cell carcinoma
Allan J. Pantuck
*
,
Amnon Zisman
, Arie Belldegrun
*
Corresponding author for this work
University of California at Los Angeles
Research output
:
Contribution to journal
›
Article
›
peer-review
13
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Gene and immune therapy for renal cell carcinoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Gene Therapy
100%
Cell-based
100%
Immune System
100%
Response Rate
100%
Tumor
100%
Immune Activation
100%
Molecular Gene
100%
Therapeutic Agents
100%
Metastasis
100%
Metastatic Renal Cell Carcinoma (mRCC)
100%
Conventional Therapy
100%
Host Immune Response
100%
Renal Cell Carcinoma
100%
Long-term Survivors
100%
Latency Period
100%
Effective Approach
100%
Poor Response
100%
Cancer Immunotherapy
100%
Gene Transfer Techniques
100%
Spontaneous Regression
100%
Immune Therapy
100%
Primary Tumor Removal
100%
Cytokine Delivery
100%
Immunotherapy Treatment
100%
Autologous Tumor Cells
100%
Gene Therapy Strategies
100%
Medicine and Dentistry
Gene Therapy
100%
Clear Cell Renal Cell Carcinoma
100%
Immunotherapy
100%
Gene Transfer
50%
Therapeutic Agent
50%
Tumor Cell
50%
Metastatic Carcinoma
50%
Spontaneous Remission
50%
Kidney Metastasis
50%
Cytokine
50%
Primary Tumor
50%
Immune Response
50%
Cancer Immunotherapy
50%
Autologous Tumor Cell
50%
Immune System
50%
Nursing and Health Professions
Neoplasm
100%
Gene Therapy
100%
Renal Cell Carcinoma
100%
Immunotherapy
100%
Remission
50%
Latent Period
50%
Primary Tumor
50%
Kidney Metastasis
50%
Cancer Immunotherapy
50%
Cytokine
50%
Cell-Based Vaccine
50%
Gene Transfer
50%
Immunology and Microbiology
Tumor Cell
100%
Immunotherapy
100%
Cytokine
50%
Gene Transfer
50%
Cancer Immunotherapy
50%
Host Immune Response
50%
Cell-Based Vaccine
50%
Immune System
50%
Pharmacology, Toxicology and Pharmaceutical Science
Renal Cell Carcinoma
100%
Immunotherapy
100%
Neoplasm
66%
Malignant Neoplasm
33%
Remission
33%
Cytokine
33%
Primary Tumor
33%
Gene Delivery
33%
Kidney Metastasis
33%